Shares of DexCom Inc. rallied 3.79% to $73.38 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 1.08% to 5,675.29 and the Dow ...

Medical device companies presented new data this week at the Advanced Technologies & Treatments for Diabetes conference.

DexCom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, today announced the launch of its first multi-region report, the "Dexcom State of Type 2 Report: Access and Attitudes Across Europe ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Dexcom (DXCM – Research Report) yesterday and set a price target of $98.00. The ...

Over 13 weeks, adults with type 2 diabetes using an automated insulin delivery (AID) system had a 0.6-percentage point ...

The use of an automated insulin delivery (AID) system reduced A1c and hyperglycemia without increasing hypoglycemia in people ...

Jaeb Center for Health Research conducted a randomized controlled trial evaluating the impact of automated insulin delivery ...

Technosphere insulin, a rapid-acting human insulin administrated through an inhaler, was associated with reductions in HbA1c ...

Insulet also recently expanded sensor integrations to include Dexcom G7 for Omnipod 5 users in the U.K. and the Netherlands. Additionally, Insulet is planning to bring Omnipod 5 to five more markets ...

Adults with insulin-treated type 2 diabetes had greater HbA1c reductions and larger improvement in time in range with use of ...